COMBINING SARTANS OF DIFFERENT DEGREE OF PPARΓ ACTIVATING CAPACITY WITH ROSUVASTATIN IN PATIENTS WITH HYPERTENSION, IMPAIRED FASTING GLUCOSE AND MIXED DYSLIPIDEMIA

被引：0
|
作者：
Rizos, C. [1 ]
Liberopoulos, E. [1 ]
Florentin, M. [1 ]
Kostapanos, M. [1 ]
Milionis, H. [1 ]
Elisaf, M. [1 ]
机构：
[1] Univ Ioannina, GR-45110 Ioannina, Greece
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2009年 / 10卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页数：1
相关论文
共 9 条
  • [1] DIFFERENTIAL EFFECT OF SARTANS WITH VARIOUS PPARγ ACTIVATING CAPACITY COMBINED WITH ROSUVASTATIN ON GLUCOSE METABOLISM INDICES
    Rizos, C.
    Milionis, H.
    Kostapanos, M.
    Florentin, M.
    Kostara, C.
    Elisaf, M.
    Liberopoulos, E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 200 - 200
  • [2] Effects of Manidipine Plus Rosuvastatin Versus Olmesartan Plus Rosuvastatin on Markers of Insulin Resistance in Patients With Impaired Fasting Glucose, Hypertension, and Mixed Dyslipidemia
    Liberopoulos, Evangelos N.
    Moutzouri, Elisavet
    Rizos, Christos V.
    Barkas, Fotis
    Liamis, George
    Elisaf, Moses S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 18 (02) : 113 - 118
  • [3] THE EFFECTS OF COMBINING ROSUVASTATIN WITH SARTANS OF DIFFERENT PPARγ ACTIVATING CAPACITY ON LOW-DENSITY LIPOPROTEIN SUBFRACTIONS AND LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2
    Rizos, C. V.
    Liberopoulos, E. N.
    Tellis, C. C.
    Florentin, M.
    Elisaf, M. S.
    Tselepis, A. D.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 22 - 22
  • [4] Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose
    Krysiak, Robert
    Handzlik, Gabriela
    Okopien, Boguslaw
    PHARMACOLOGICAL REPORTS, 2010, 62 (06) : 1099 - 1107
  • [5] Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose
    Robert Krysiak
    Gabriela Handzlik
    Bogusław Okopień
    Pharmacological Reports, 2010, 62 : 1099 - 1107
  • [6] The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-γ activating capacity on plasma 8-isoprostane prostaglandin F2a levels
    Rizos, Christos V.
    Liberopoulos, Evangelos N.
    Tellis, Constantinos C.
    Tselepis, Alexandros D.
    Elisaf, Moses S.
    ARCHIVES OF MEDICAL SCIENCE, 2013, 9 (01) : 172 - 176
  • [7] Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPARγ-Activating Capacity: Effects on High-Density Lipoprotein Subfractions and Associated Enzymes
    Rizos, Christos V.
    Liberopoulos, Evangelos N.
    Tellis, Kostas
    DiNicolantonio, James J.
    Tselepis, Alexandros D.
    Elisaf, Moses S.
    ANGIOLOGY, 2015, 66 (01) : 36 - 42
  • [8] Combining Rosuvastatin with Sartans of Different Peroxisome Proliferator-Activated Receptor-γ Activating Capacity Is Not Associated with Different Changes in Low-Density Lipoprotein Subfractions and Plasma Lipoprotein-Associated Phospholipase A2
    Rizos, Christos V.
    Liberopoulos, Evangelos N.
    Tellis, Constantinos C.
    Florentin, Matilda
    Elisaf, Moses S.
    Tselepis, Alexandros D.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2011, 9 (03) : 217 - 223
  • [9] Effects of Rosuvastatin Combined With Olmesartan, Irbesartan, or Telmisartan on Indices of Glucose Metabolism in Greek Adults With Impaired Fasting Glucose, Hypertension, and Mixed Hyperlipidemia: A 24-Week, Randomized, Open-Label, Prospective Study
    Rizos, Christos V.
    Milionis, Haralampos J.
    Kostapanos, Michael S.
    Florentin, Matilda
    Kostara, Christina E.
    Elisaf, Moses S.
    Liberopoulos, Evangelos N.
    CLINICAL THERAPEUTICS, 2010, 32 (03) : 492 - 505
1